CORRESP Filing
Nasus Pharma Ltd
Date: Aug. 8, 2025 · CIK: 0002029039 · Accession: 0001493152-25-011757
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288582
Letter
Nasus Pharma Ltd.
Yigal Alon 65
Tel Aviv, Israel 6744317
August 8, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Nasus Pharma Ltd. (CIK: 0002029039)
Registration Statement No. 333-288582 on Form F-1 (the "Registration Statement")
Ladies and Gentlemen:
Nasus Pharma Ltd. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), so that it may become effective on Monday August 11, 2025 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable. By separate letter, the underwriters of the issuance of the securities being registered have joined in this request for acceleration.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Eric Victorson, Esq. at (212) 660-3092 of Sullivan & Worcester LLP and that such effectiveness also be confirmed in writing.
Very
truly yours,
Nasus
Pharma Ltd.
Show Raw Text
CORRESP 1 filename1.htm Nasus Pharma Ltd. Yigal Alon 65 Tel Aviv, Israel 6744317 August 8, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Nasus Pharma Ltd. (CIK: 0002029039) Registration Statement No. 333-288582 on Form F-1 (the "Registration Statement") Ladies and Gentlemen: Nasus Pharma Ltd. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Securities Act "), so that it may become effective on Monday August 11, 2025 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable. By separate letter, the underwriters of the issuance of the securities being registered have joined in this request for acceleration. The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement. The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Eric Victorson, Esq. at (212) 660-3092 of Sullivan & Worcester LLP and that such effectiveness also be confirmed in writing. Very truly yours, Nasus Pharma Ltd. By: /s/ Dan Teleman Name: Dan Teleman Title: Chief Executive Officer